Previous 10 | Next 10 |
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the M...
Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. President and CEO of the ...
Alimera Sciences ([[ALIM]] +13.5%) announces preliminary consolidated net revenue for Q4 in excess of $13.5M and annual 2020 consolidated net revenue in excess of $50.5M.Company anticipates that cash on December 31, 2020 will be $11.2M compared to $11.3M on September 30, 2020.“Whi...
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary conso...
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H...
EyePoint Pharmaceuticals (EYPT) announces a royalty monetization agreement with SWK Holdings (SWKH) for royalties payable to EYPT under its license agreement with Alimera Sciences (ALIM) for ILUVIEN.EyePoint has received a one-time $16.5M payment from SWK and, in return, SWK is entitled to re...
AnPac Bio-Medical Science (ANPC) +99% as company makes significant progress in detecting pre-cancer diseases.Arvinas (ARVN) +74% after releasing interim clinical data of PROTAC® protein degraders.Veru (VERU) +57% on positive phase 2 clinical trial results for Enobosarm.Syn...
ATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Irish subsidiary, ha...
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that CEO Rick Eiswirth will present a corporate over...
The following slide deck was published by Alimera Sciences, Inc. in conjunction with this event. For further details see: Alimera Sciences (ALIM) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...